April 2026 issue
April 30, 2026 | The regulatory pathway for medical devices in the U.K. remains unsettled several years after Brexit. While the U.K. has sought to establish a distinct regulatory identity through the UK Medical Devices Regulations and the UKCA (UK Conformity Assessed) mark, the practical landscape for manufacturers remains closely tied to Europe.
For U.S. and European neurotechnology companies, the result is a regulatory environment that is not simply “post-Brexit,” but rather one shaped by overlapping systems: the legacy U.K. framework, the European Union Medical Device Regulation, continued recognition of CE-marked products, and the special status of Northern Ireland. Neurotech Reports spoke with Martin Becker, regulatory lead for health tech at CPI, a leading independent U.K.-based technology innovation center.
“The UK MDR is fundamentally based on earlier European laws that were enforced in the European Union prior to 2017,” Becker said. Those laws included the Active Implantable Medical Device Directive, the Medical Device Directive, and the In Vitro Diagnostic Directive, which were developed in the 1990s and remain embedded in U.K. law.
That creates a notable contrast with the EU. The EU MDR and IVDR, adopted in 2017, imposed a more rigorous regulatory regime, with greater emphasis on clinical evidence, post-market surveillance, traceability, and lifecycle oversight. Gone are the days when U.S. companies could readily enter the European Union with a CE mark years before entering the U.S. Becker said the current UK MDR remains less developed than the EU MDR/IVDR framework in several key areas.
The U.K. has begun to close part of that gap. One major area is post-market surveillance or PMS. The new PMS requirements apply in Great Britain from June 16, 2025. The EU MDR placed substantial new emphasis on post-market monitoring, and the U.K. has moved to strengthen its own PMS requirements. “The EU MDR and EU IVDR focused a lot on post-market surveillance, and so the U.K. effectively has tried to close a gap there,” Becker said. “So it is closer now to European law, but there’s still a difference.”
For manufacturers, the immediate strategic question is whether to pursue UKCA marking, CE marking, or both. In principle, UKCA is the U.K.’s post-Brexit conformity mark for Great Britain. In practice, CE-marked medical devices continue to be accepted in Great Britain under extended transition timelines—until June 30, 2028 for many medical devices and June 30, 2030 for IVDs, depending on device type and applicable EU legislation, according to Becker.
This has reduced urgency around UKCA. Many companies, especially those with international ambitions, are likely to prioritize CE marking because it offers access to the much larger EU market and remains sufficient for the U.K. during the transition period. Becker said the issue is magnified by the fact that a large share of devices used in the National Health Service come from Europe, making continued access to CE-marked products commercially and politically important.
The future role of UKCA is therefore uncertain. The Medicines and Healthcare products Regulatory Agency, or MHRA, which regulates medicines and medical devices in the U.K., has been consulting on whether CE-marked products should continue to be accepted in Great Britain indefinitely. If that happens, Becker said, “it puts a question mark around UKCA mark overall. What’s the purpose of it?” In that scenario, UKCA may be relevant mainly for companies targeting only Great Britain, rather than firms pursuing broader European or global commercialization.
Northern Ireland adds another complication. Under the Windsor Framework, Northern Ireland continues to follow EU MDR and IVDR rules for medical devices. That means a UKCA mark alone does not provide access to the entire U.K. “The irony is, if you follow the UK MDR at this point in time to get UKCA marking, that doesn’t even get you into the full breadth of the U.K., including Northern Ireland,” Becker said. “Over there, you have to deal with European law anyway.”
This is where Ireland matters indirectly. The Republic of Ireland remains fully within the EU regulatory system, while Northern Ireland remains aligned with EU MDR for medical devices. For manufacturers operating across the island of Ireland, or seeking full U.K. and EU access, CE marking remains central. A company seeking the whole U.K. market may need both UKCA for Great Britain and CE marking for Northern Ireland.
The broader policy challenge is that the U.K. wants regulatory autonomy but not unnecessary trade friction. Becker noted that simply adopting EU law is politically difficult because the U.K. no longer has a formal role in shaping it. At the same time, if UKCA and CE requirements diverge too far, the U.K. risks creating barriers between itself and its most important nearby medical device market.
One potential solution is international reliance. Rather than fully duplicating EU, U.S., or other regulatory reviews, the U.K. is exploring ways to rely on work already performed by trusted regulators. “Some of the work that has been done, for example, to get UKCA marking might very well be acceptable also to contribute to get CE marking in the EU,” Becker said, adding that the same concept could apply to FDA and other approvals.
For neurotechnology companies, the practical message is straightforward. The U.K. can be an attractive market, but its regulatory pathway should not be viewed in isolation. Companies developing active implantables, neuromodulation systems, or other advanced devices will need to consider U.K., EU, and possibly U.S. regulatory strategies in parallel.
Despite the uncertainty, there remains the possibility that U.K. medical device regulation will be more in line with U.S. FDA policies. Earlier this month, MHRA announced that it is stepping up its collaboration with the FDA to support faster access to safe and innovative medical technologies in the future for patients in both countries.
The MHRA and FDA will work closely on options to improve and align regulations for medical devices. This includes exploring future mutual recognition mechanisms (ways to recognize parts of the individual approval processes), reducing duplication for manufacturers, and streamlining approval processes to help patients access new medical technologies sooner.
Both regulators’ work will remain independent and ensure strict safety standards are maintained.
“Closer working between the U.K. and the U.S. means that future innovative medical technologies—better diagnostics, smarter devices, life-changing treatments—can reach NHS patients sooner, without compromising on the safety standards we rightly expect,” said Health Innovation and Safety Minister Zubir Ahmed. “This is the correct next step. We’ve already acted to secure improved access to life-changing medicines for NHS patients. Now we’re working to make sure the devices and technologies that go alongside them follow the same path.
“This marks an exciting moment for U.K innovation. By strengthening our working relationship with the FDA, we are allowing cutting edge medical technologies to reach patients faster and more efficiently than ever before,” said Lawrence Tallon, MHRA chief executive. “This is exactly the kind of partnership that enables the UK to stay at the forefront of global life sciences.
For now, however, UK MDR remains a transitional framework. The U.K. has diverged from Europe in law, but continues to rely heavily on Europe in practice. Whether UKCA becomes a durable independent pathway or a secondary route alongside CE marking will depend on MHRA policy choices over the next several years.
